Amiodarone Association With Severe Primary Graft Dysfunction and Vasoactive Inotropic Score After Heart Transplantation.

IF 6.7 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiac Failure Pub Date : 2025-06-17 DOI:10.1016/j.cardfail.2025.05.015

Natalie S Dorsey, Alec E Biscopink, Brian A Houston, Jessica Atkins, Arman Kilic, Mathew Gregoski, Ryan J Tedford, Jan M Griffin

{"title":"Amiodarone Association With Severe Primary Graft Dysfunction and Vasoactive Inotropic Score After Heart Transplantation.","authors":"Natalie S Dorsey, Alec E Biscopink, Brian A Houston, Jessica Atkins, Arman Kilic, Mathew Gregoski, Ryan J Tedford, Jan M Griffin","doi":"10.1016/j.cardfail.2025.05.015","DOIUrl":null,"url":null,"abstract":"Background: The impact of amiodarone on severe primary graft dysfunction (PGD) and vasoactive inotropic scores (VISs) following heart transplantation (HT) is unclear.Methods and results: We investigated these relationships through a retrospective study of 183 consecutive patients >18 years old who underwent isolated HT at our center from 2018-2023. Data for amiodarone use in the 6 months pre-HT were recorded (duration, cumulative dosage, use at HT, last dose pre-HT). Of the 69 patients in the amiodarone cohort, 37 were considered to be taking amiodarone at the time of transplant. The primary endpoint was severe PGD, as defined by the International Society of Heart and Lung Transplantation (ISHLT) criteria. Post-HT VISs were calculated as defined by ISHLT.Conclusions: Amiodarone was not associated with severe PGD (P = 0.67), and there was no difference in post-transplant VISs based on amiodarone exposure [20 (19.6) vs 16.3 (13.8); P = 0.122] (Fig. 1). This study supports similar hemodynamic profiles post-HT, regardless of amiodarone use.","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7000,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiac Failure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cardfail.2025.05.015","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The impact of amiodarone on severe primary graft dysfunction (PGD) and vasoactive inotropic scores (VISs) following heart transplantation (HT) is unclear.

Methods and results: We investigated these relationships through a retrospective study of 183 consecutive patients >18 years old who underwent isolated HT at our center from 2018-2023. Data for amiodarone use in the 6 months pre-HT were recorded (duration, cumulative dosage, use at HT, last dose pre-HT). Of the 69 patients in the amiodarone cohort, 37 were considered to be taking amiodarone at the time of transplant. The primary endpoint was severe PGD, as defined by the International Society of Heart and Lung Transplantation (ISHLT) criteria. Post-HT VISs were calculated as defined by ISHLT.

Conclusions: Amiodarone was not associated with severe PGD (P = 0.67), and there was no difference in post-transplant VISs based on amiodarone exposure [20 (19.6) vs 16.3 (13.8); P = 0.122] (Fig. 1). This study supports similar hemodynamic profiles post-HT, regardless of amiodarone use.

查看原文本刊更多论文

胺碘酮与心脏移植后严重原发性移植物功能障碍和血管活性肌力评分的关系。

背景：胺碘酮对心脏移植（HT）后严重原发性移植物功能障碍（PGD）和血管活性肌力评分（VIS）的影响尚不清楚。方法和结果：我们通过一项回顾性研究，调查了2018-2023年在我们中心连续接受隔离性HT治疗的183例bb0 - 18岁患者的相关性。记录治疗前6个月胺碘酮使用情况（持续时间、累计剂量、治疗时使用情况、治疗前最后一次剂量）。在胺碘酮队列的69例患者中，37例被认为在移植时使用胺碘酮。主要终点是国际心肺移植学会（ISHLT）标准定义的严重PGD。ht后VIS按ISHLT定义计算。结论：胺碘酮与严重PGD无关（p = 0.67），并且基于胺碘酮暴露的移植后VIS无差异（20 [19.6]vs 16.3 [13.8], p=0.122，图1）。这项研究支持类似的血流动力学特征后ht与胺碘酮使用无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cardiac Failure 医学-心血管系统

CiteScore

7.80

自引率

8.30%

发文量

653

审稿时长

21 days

期刊介绍： Journal of Cardiac Failure publishes original, peer-reviewed communications of scientific excellence and review articles on clinical research, basic human studies, animal studies, and bench research with potential clinical applications to heart failure - pathogenesis, etiology, epidemiology, pathophysiological mechanisms, assessment, prevention, and treatment.